Split dose ATG strategy prevents grade III-IV acute GVHD and is associated with immune surrogates of GVL

Zaid Al-Kadhimi; Samuel Pirruccello; Zartash Gul; Lori Maness-Harris; Vijaya Raj Bhatt; Krishna Gundabolu; Jane Yuan; Matthew Lunning; Gregory Bociek; Christopher D’Angelo; Avyakta Kallam; James Armitage; Khansa Abdullah; Angela Hunter; Sarah Mccaslin; Elizabeth Lyden; Lynnette Smith; Michael Callahan; Kathryn Cole; Steven Hinrichs; James Talmadge; Julie Vose

doi:10.1038/s41409-022-01772-w

Split dose ATG strategy prevents grade III-IV acute GVHD and is associated with immune surrogates of GVL

Zaid Al-Kadhimi, Samuel Pirruccello, Zartash Gul, Lori Maness-Harris, Vijaya Raj Bhatt, Krishna Gundabolu, Jane Yuan, Matthew Lunning, Gregory Bociek, Christopher D’Angelo, Avyakta Kallam, James Armitage, Khansa Abdullah, Angela Hunter, Sarah Mccaslin, Elizabeth Lyden, Lynnette Smith, Michael Callahan, Kathryn Cole, Steven HinrichsJames Talmadge, Julie Vose

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	1629-1631
Number of pages	3
Journal	Bone marrow transplantation
Volume	57
Issue number	10
DOIs	https://doi.org/10.1038/s41409-022-01772-w
State	Published - Oct 2022

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1038/s41409-022-01772-w

Cite this

Al-Kadhimi, Z., Pirruccello, S., Gul, Z., Maness-Harris, L., Bhatt, V. R., Gundabolu, K., Yuan, J., Lunning, M., Bociek, G., D’Angelo, C., Kallam, A., Armitage, J., Abdullah, K., Hunter, A., Mccaslin, S., Lyden, E., Smith, L., Callahan, M., Cole, K., ... Vose, J. (2022). Split dose ATG strategy prevents grade III-IV acute GVHD and is associated with immune surrogates of GVL. Bone marrow transplantation, 57(10), 1629-1631. https://doi.org/10.1038/s41409-022-01772-w

Al-Kadhimi, Z , Pirruccello, S, Gul, Z, Maness-Harris, L , Bhatt, VR , Gundabolu, K, Yuan, J, Lunning, M , Bociek, G , D’Angelo, C , Kallam, A , Armitage, J, Abdullah, K, Hunter, A, Mccaslin, S, Lyden, E, Smith, L, Callahan, M, Cole, K, Hinrichs, S, Talmadge, J & Vose, J 2022, 'Split dose ATG strategy prevents grade III-IV acute GVHD and is associated with immune surrogates of GVL', Bone marrow transplantation, vol. 57, no. 10, pp. 1629-1631. https://doi.org/10.1038/s41409-022-01772-w

@article{1a76ed858e834d77a542dfd2c4dfe515,

title = "Split dose ATG strategy prevents grade III-IV acute GVHD and is associated with immune surrogates of GVL",

author = "Zaid Al-Kadhimi and Samuel Pirruccello and Zartash Gul and Lori Maness-Harris and Bhatt, {Vijaya Raj} and Krishna Gundabolu and Jane Yuan and Matthew Lunning and Gregory Bociek and Christopher D{\textquoteright}Angelo and Avyakta Kallam and James Armitage and Khansa Abdullah and Angela Hunter and Sarah Mccaslin and Elizabeth Lyden and Lynnette Smith and Michael Callahan and Kathryn Cole and Steven Hinrichs and James Talmadge and Julie Vose",

note = "Funding Information: This research is supported with funds from The University of Nebraska Foundation. Presented in abstract form at the 57 European bone marrow transplant meeting, Prague, Czech March 2022. th Funding Information: VRB reports participating in Safety Monitoring Committee for Protagonist, and receiving consulting fees from Genentech, Incyte, Servier Pharmaceuticals LLC, and Abbvie, research funding (institutional) from Abbvie, Pfizer, Incyte, Jazz, and National Marrow Donor Program, and drug support (institutional) from Oncoceutics for a trial. KG consulting: Bayer consumer care, CTI biopharma, BMS, Blueprint Medicines, Jazz Pharmaceuticals, BioMarin Pharmaceuticals. Institutional funding: Samus therapeutics, Incyte, Pfizer, Autolus therapeutics. JV Consulting: Morphosys, Abbvie, Janssen, Astra-Zeneca, MEI Pharma, Daiichi Sankyo, Johnson and Johnson, Pharmacyclics, Genentech. Research: Loxo Pharma, Novartis, Kite. ",

year = "2022",

month = oct,

doi = "10.1038/s41409-022-01772-w",

language = "English (US)",

volume = "57",

pages = "1629--1631",

journal = "Bone marrow transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - Split dose ATG strategy prevents grade III-IV acute GVHD and is associated with immune surrogates of GVL

AU - Al-Kadhimi, Zaid

AU - Pirruccello, Samuel

AU - Gul, Zartash

AU - Maness-Harris, Lori

AU - Bhatt, Vijaya Raj

AU - Gundabolu, Krishna

AU - Yuan, Jane

AU - Lunning, Matthew

AU - Bociek, Gregory

AU - D’Angelo, Christopher

AU - Kallam, Avyakta

AU - Armitage, James

AU - Abdullah, Khansa

AU - Hunter, Angela

AU - Mccaslin, Sarah

AU - Lyden, Elizabeth

AU - Smith, Lynnette

AU - Callahan, Michael

AU - Cole, Kathryn

AU - Hinrichs, Steven

AU - Talmadge, James

AU - Vose, Julie

N1 - Funding Information: This research is supported with funds from The University of Nebraska Foundation. Presented in abstract form at the 57 European bone marrow transplant meeting, Prague, Czech March 2022. th Funding Information: VRB reports participating in Safety Monitoring Committee for Protagonist, and receiving consulting fees from Genentech, Incyte, Servier Pharmaceuticals LLC, and Abbvie, research funding (institutional) from Abbvie, Pfizer, Incyte, Jazz, and National Marrow Donor Program, and drug support (institutional) from Oncoceutics for a trial. KG consulting: Bayer consumer care, CTI biopharma, BMS, Blueprint Medicines, Jazz Pharmaceuticals, BioMarin Pharmaceuticals. Institutional funding: Samus therapeutics, Incyte, Pfizer, Autolus therapeutics. JV Consulting: Morphosys, Abbvie, Janssen, Astra-Zeneca, MEI Pharma, Daiichi Sankyo, Johnson and Johnson, Pharmacyclics, Genentech. Research: Loxo Pharma, Novartis, Kite.

PY - 2022/10

Y1 - 2022/10

UR - http://www.scopus.com/inward/record.url?scp=85135774672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85135774672&partnerID=8YFLogxK

U2 - 10.1038/s41409-022-01772-w

DO - 10.1038/s41409-022-01772-w

M3 - Letter

C2 - 35953707

AN - SCOPUS:85135774672

SN - 0268-3369

VL - 57

SP - 1629

EP - 1631

JO - Bone marrow transplantation

JF - Bone marrow transplantation

IS - 10

ER -

Split dose ATG strategy prevents grade III-IV acute GVHD and is associated with immune surrogates of GVL

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this